首页> 外文期刊>The Lancet >Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.
【24h】

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.

机译:口服维生素D3和钙对老年人低创伤性骨折的二级预防(钙或维生素D随机评估,RECORD):一项随机安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Elderly people who have a fracture are at high risk of another. Vitamin D and calcium supplements are often recommended for fracture prevention. We aimed to assess whether vitamin D3 and calcium, either alone or in combination, were effective in prevention of secondary fractures. METHODS: In a factorial-design trial, 5292 people aged 70 years or older (4481 [85%] of whom were women) who were mobile before developing a low-trauma fracture were randomly assigned 800 IU daily oral vitamin D3, 1000 mg calcium, oral vitamin D3 (800 IU per day) combined with calcium (1000 mg per day), or placebo. Participants who were recruited in 21 UK hospitals were followed up for between 24 months and 62 months. Analysis was by intention-to-treat and the primary outcome was new low-energy fractures. FINDINGS: 698 (13%) of 5292 participants had a new low-trauma fracture, 183 (26%) of which were of the hip. The incidence of new, low-trauma fractures did not differ significantly between participants allocated calcium and those who were not (331 [12.6%] of 2617 vs 367 [13.7%] of 2675; hazard ratio (HR) 0.94 [95% CI 0.81-1.09]); between participants allocated vitamin D3 and those who were not (353 [13.3%] of 2649 vs 345 [13.1%] of 2643; 1.02 [0.88-1.19]); or between those allocated combination treatment and those assigned placebo (165 [12.6%] of 1306 vs 179 [13.4%] of 1332; HR for interaction term 1.01 [0.75-1.36]). The groups did not differ in the incidence of all-new fractures, fractures confirmed by radiography, hip fractures, death, number of falls, or quality of life. By 24 months, 2886 (54.5%) of 5292 were still taking tablets, 451 (8.5%) had died, 58 (1.1%) had withdrawn, and 1897 (35.8%) had stopped taking tablets but were still providing data for at least the main outcomes. Compliance with tablets containing calcium was significantly lower (difference: 9.4% [95% CI 6.6-12.2]), partly because of gastrointestinal symptoms. However, potentially serious adverse events were rare and did not differ between groups. INTERPRETATION: The findings do not support routine oral supplementation with calcium and vitamin D3, either alone or in combination, for the prevention of further fractures in previously mobile elderly people.
机译:背景:患有骨折的老年人极有可能患另一种骨折。通常建议使用维生素D和钙补充剂预防骨折。我们旨在评估维生素D3和钙(单独或组合使用)在预防继发性骨折方面是否有效。方法:在一项析因设计试验中,对5292名年龄在70岁以上的人(其中4481 [85%]是女性)在发生低创伤骨折之前可活动性进行了随机分配,每天口服800 IU维生素D3、1000 mg钙,口服维生素D3(每天800 IU)和钙(每天1000 mg)或安慰剂。在英国21家医院招募的参与者进行了24个月至62个月的随访。通过意向性治疗进行分析,主要结果是新的低能量骨折。结果:5292名参与者中有698名(13%)有新的低创伤性骨折,其中183名(26%)为髋部骨折。新的低创伤性骨折的发生率与未分配钙的参与者之间没有显着差异(2617年的331 [12.6%]与2675年的367 [13.7%];危险比(HR)0.94 [95%CI 0.81] -1.09]);分配维生素D3的参与者与未分配维生素D3的参与者之间(2649年的353 [13.3%]比2643的345 [13.1%]; 1.02 [0.88-1.19]);或在分配了联合治疗的患者和分配了安慰剂的患者之间(1306年的165 [12.6%]与1332年的179 [13.4%];相互作用项的HR为1.01 [0.75-1.36])。这些组在新骨折的发生率,放射线照相证实的骨折,髋部骨折,死亡,跌倒次数或生活质量方面没有差异。到24个月时,在5292个中,有2886个(54.5%)仍在服用药片,死亡451个(8.5%),撤回了58个(1.1%),还有1897个(35.8%)停止服用药片,但仍至少提供了数据主要结果。对含钙片剂的依从性明显降低(差异:9.4%[95%CI 6.6-12.2]),部分原因是胃肠道症状。但是,潜在的严重不良事件很少见,各组之间没有差异。解释:研究结果不支持常规口服钙和维生素D3单独或组合补充口服,以防止以前活动的老年人进一步骨折。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号